Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
28 Juni 2023 - 2:31PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13A-16 OR 15D-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2023
Commission File Number: 001-38283
InflaRx N.V.
(Translation of registrant's name into English)
Winzerlaer Str. 2
07745 Jena, Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
On June 28, 2023, InflaRx N.V. issued a press release titled “InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer.” A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
EXHIBIT INDEX
|
Exhibit No.
|
|
Description
|
|
|
|
Press Release, dated June 28, 2023.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
INFLARX N.V.
|
| |
|
|
Date: June 28, 2023
|
By:
|
/s/ Niels Riedemann
|
| |
Name:
|
Niels Riedemann
|
| |
Title:
|
Chief Executive Officer
|
4
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
Von Mai 2024 bis Jun 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
Von Jun 2023 bis Jun 2024
